Literature DB >> 1675130

'Role of bone marrow stromal cells in the growth of human multiple myeloma.

F Caligaris-Cappio1, L Bergui, M G Gregoretti, G Gaidano, M Gaboli, M Schena, A Z Zallone, P C Marchisio.   

Abstract

We have verified the hypothesis that multiple myeloma (MM) may be disseminated by circulating clonogenic cells that selectively home to the bone marrow (BM) to receive the signal(s) leading to proliferation, terminal differentiation, and production of the osteoclast activating factors. Long-term cultures of stromal cells have been developed from the BM of nine patients with MM. These cells were mostly fibroblast-like elements, interspersed with a proportion of scattered macrophages and rare osteoclasts. BM stromal cells were CD54+, produced high levels of interleukin-6 (IL-6) and measurable amounts of IL-1 beta, and were used as feeder layers for autologous peripheral blood mononuclear cells (PBMC). After 3 weeks of cocultures, monoclonal B lymphocytes and plasma cells, derived from PBMC, developed and the number of osteoclasts significantly increased. Both populations grew tightly adherent to the stromal cell layer and their expansion was matched by a sharp increase of IL-6 and by the appearance of IL-3 in the culture supernatant. These data attribute to BM stromal cells a critical role in supporting the growth of B lymphocytes, plasma cells, and osteoclasts and the in vivo dissemination of MM.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1675130

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  42 in total

1.  Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.

Authors:  M Chesi; E Nardini; L A Brents; E Schröck; T Ried; W M Kuehl; P L Bergsagel
Journal:  Nat Genet       Date:  1997-07       Impact factor: 38.330

2.  Autocrine and Paracrine Interactions between Multiple Myeloma Cells and Bone Marrow Stromal Cells by Growth Arrest-specific Gene 6 Cross-talk with Interleukin-6.

Authors:  Miki Furukawa; Hiroshi Ohkawara; Kazuei Ogawa; Kazuhiko Ikeda; Koki Ueda; Akiko Shichishima-Nakamura; Emi Ito; Jun-Ichi Imai; Yuka Yanagisawa; Reiko Honma; Shinya Watanabe; Satoshi Waguri; Takayuki Ikezoe; Yasuchika Takeishi
Journal:  J Biol Chem       Date:  2017-01-31       Impact factor: 5.157

Review 3.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

4.  Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone.

Authors:  Xin Li; Wen Ling; Angela Pennisi; Yuping Wang; Sharmin Khan; Mohammad Heidaran; Ajai Pal; Xiaokui Zhang; Shuyang He; Andy Zeitlin; Stewart Abbot; Herbert Faleck; Robert Hariri; John D Shaughnessy; Frits van Rhee; Bijay Nair; Bart Barlogie; Joshua Epstein; Shmuel Yaccoby
Journal:  Stem Cells       Date:  2011-02       Impact factor: 6.277

5.  Fas/Fas ligand (FasL)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells.

Authors:  M A Frassanito; F Silvestris; N Silvestris; P Cafforio; G Camarda; G Iodice; F Dammacco
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

6.  A novel flow cytometric assay for the quantification of adhesion of subsets within a heterogeneous cell population; analysis of lymphocyte function-associated antigen-1 (LFA-1)-mediated binding of bone marrow-derived primary tumour cells of patients with multiple myeloma.

Authors:  E J Ahsmann; R J Benschop; T D de Gruyl; J A Faber; H M Lokhorst; A C Bloem
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

7.  Development of plasma cell tumors during treatment of multiple myeloma.

Authors:  G Vaiopoulos; N Viniou; E Plata; K Konstantopoulos; A Andreopoulos; Y Rombos; J Meletis; D Loukopoulos; X Yataganas
Journal:  Ann Hematol       Date:  1996-05       Impact factor: 3.673

8.  Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production.

Authors:  Masahiro Abe; Kenji Hiura; Shuji Ozaki; Shinsuke Kido; Toshio Matsumoto
Journal:  J Bone Miner Metab       Date:  2008-12-05       Impact factor: 2.626

Review 9.  The role of tumour-stromal interactions in modifying drug response: challenges and opportunities.

Authors:  Douglas W McMillin; Joseph M Negri; Constantine S Mitsiades
Journal:  Nat Rev Drug Discov       Date:  2013-03       Impact factor: 84.694

10.  Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells.

Authors:  Barbara Zdzisińska; Agnieszka Bojarska-Junak; Anna Dmoszyńska; Martyna Kandefer-Szerszeń
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-05-30       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.